

# iStent infinite® Trabecular Micro-Bypass System

## INSTRUCTIONS FOR USE

### **DEVICE DESCRIPTION**

Catalogue #	Description
iS3	Glaukos® iStent infinite® System Model iS3 with three (3) G2-W Stearalkonium Heparin coated Trabecular Micro-Bypass Stents preloaded in one injector

The iStent infinite® System contains three intraocular stents that are manufactured from titanium and coated with stearalkonium heparin. Each stent has a single piece design, is approximately 360 microns in height and 360 microns in diameter. The injector has been designed by Glaukos Corporation to implant three Model G2-W stents through a single incision into Schlemm's canal.

The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure.

Materials to which patients can be exposed: 100% implant-grade titanium alloy (Ti6Al4V ELI) and 100% Stearalkonium Heparin (biocompatible stent coating). Note: the heparin is from a porcine source.

### **HOW SUPPLIED**

Each iStent infinite System is provided sterile in a blister tray (only the inner contents of the blister tray are sterile). Three stents are already assembled onto the single-use injector. The blister tray lid is labeled with the required product identification information. A lot number and serial number are provided on the labeling. The iStent infinite System is sterilized by gamma irradiation.

The expiration date on the device package (tray lid) is the sterility expiration date. In addition, there is a sterility expiration date that is clearly indicated on the outside of the unit carton. Sterility is assured if the tray seal is not broken, punctured or damaged until the expiration date. This device should not be used past the indicated sterility expiration date.

### **INTENDED USE**

Intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma, or pigmentary glaucoma.

### **INDICATIONS FOR USE**

The iStent infinite System is intended to reduce intraocular pressure safely and effectively in adult patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma.

The device is safe and effective when implanted in combination with or without cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction.

The device may also be implanted in patients who continue to have elevated intraocular pressure despite

prior treatment with glaucoma medications and/or conventional glaucoma surgery.

### **INTENDED PATIENT POPULATION**

Adult patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma.

### **CONTRAINDICATIONS**

The iStent infinite System is contraindicated under the following circumstances or conditions:

- In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations.
- In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

### **EXPECTED CLINICAL BENEFITS**

The iStent infinite provides a surgical option that has the ability to be performed at the same time as cataract surgery or as a standalone procedure (i.e., without cataract) for assisting in the delay of open-angle glaucoma disease progression and thereby preserving visual function and preventing future visual field loss.

### **EXPECTED LIFETIME**

The iStent infinite is designed to last throughout the patient's lifetime.

### **PERFORMANCE CHARACTERISTICS**

The iStent infinite is designed to provide clinical performance of IOP lowering for at least 12 months. A pivotal clinical trial evaluated the safety and performance of the iStent infinite (performed as a standalone procedure) in adult subjects with open-angle glaucoma uncontrolled by prior surgical or medical therapy. The iStent infinite Model iS3 (3 G2-W stents) were implanted in 72 eyes with open-angle glaucoma not controlled despite prior treatment with filtering procedures, cilioablative procedures, and/or maximally-tolerated medical therapy (MTMT). Subjects were followed for 12 months.

The majority of subjects, 76.1%, met the responder endpoint achieving  $\geq 20\%$  reduction in mean diurnal intraocular pressure (MDIOP) from baseline at 12 months on the same number or fewer ocular hypotensive medication classes as baseline. The change from baseline in MDIOP at 12 months was -5.9 mmHg. Further, 93% of the 71 subjects with 12 month data experienced some level of MDIOP reduction from baseline without secondary surgical interventions. When analyzing the two subgroups, 73.4% of eyes who had failed surgery and 90.9% of eyes uncontrolled on MTMT achieved the responder endpoint and demonstrated a change from baseline in MDIOP at M12 of -5.5 mmHg and -8.1 mmHg, respectively. The study also demonstrated that subjects were able to reduce their glaucoma medication.

Regarding safety, there were no unanticipated adverse device effects and no serious ocular adverse events.

## iStent infinite® Trabecular Micro-Bypass System INSTRUCTIONS FOR USE

The Summary of Safety and Clinical Performance of the iS3 with UDI-DI 00853704002333 can be found at:

<https://ec.europa.eu/tools/eudamed/#/screen/search-device>.

### **INSTRUCTIONS FOR USE**

- 1) Remove the Stent Delivery Button Lock from the injector.
- 2) Make a corneal incision of adequate length to allow entry of the introducer tip of the injector into the anterior chamber. Recommended incision location is the temporal peripheral cornea for either eye. Ophthalmic viscoelastic (cohesive) should be used to form the anterior chamber, as necessary. Deepen the anterior chamber by injecting with viscoelastic as needed, being careful not to overinflate.
- 3) The iStent infinite injector insertion steps are as follows: With the gonioscope removed from the cornea, insert the injector Introducer Tip through the clear corneal incision into the anterior chamber. Once the Introducer Tip has been inserted through the corneal incision, the Introducer Tip auto-retracts exposing the Insertion Tube and Trocar tip. Advance the Insertion Tube to the pupillary margin toward the targeted trabecular meshwork tissue (i.e., the *ab interno* approach). Take care to avoid contact with the IOL, iris, or cornea.
- 4) Place a commercially available gonioscope on the cornea and position the patient and surgical microscope as needed to visualize the trabecular meshwork through the gonioscope on the nasal side of the eye.
- 5) Advance the Insertion Tube containing the trocar towards the TM (just above the scleral spur) and penetrate the trocar tip through the center of the TM. The trocar is used to not only penetrate the TM, but will remain in the tissue to act as an axial guide for the stent as the stent traverses over the trocar through to Schlemm's canal.
- 6) Gently hold the Insertion Tube against the TM and apply appropriate pressure to slightly indent or "dimple" the tissue (tissue should stretch just enough to form a "V" when pressing on the TM).
- 7) Slowly squeeze and hold down the Stent Delivery Button to automatically inject the stent head through the TM and into Schlemm's canal. Look through the window in the insertion tube to verify that the stent has been implanted properly.
- 8) Withdraw the injector straight back from the stent, and verify that the stent is well-positioned and secured in the TM.
- 9) Actuate the Singulator to prepare the next stent for implantation. Listen for two audible clicks, and verify that the next stent is visible in the window of the insertion tube.
- 10) Carefully relocate the tip of the injector approximately 2 clock hours away from the first stent for implantation of the second stent. Implant the next stent using the same procedure as the previous stent.
- 11) Repeat steps 9 and 10 for the third stent, placing the third stent approximately 2 clock hours away from either of the first two stents.
- 12) Remove the injector from the eye.
- 13) Irrigate the anterior chamber with balanced salt solution (BSS) through the corneal wound to

remove all viscoelastic. Press down on the posterior edge of the incision as needed to facilitate complete removal of viscoelastic.

- 14) Inflate the anterior chamber with saline solution as needed to achieve normal physiologic pressure.
- 15) Ensure that the corneal incision is sealed.

### **Retrieval of an Implanted Stent**

- 1) Prep the patient as one would for stent implantation surgery.
- 2) Re-open the eye at the preferred location in order to reach the stent. A clear corneal incision measuring approximately 1.5mm in length is recommended.
- 3) Use cohesive viscoelastic to inflate the anterior chamber to create access to the stent's location, move the stent away from a delicate structure if loose, and/or protect intraocular tissues.
- 4) Use a commercially available gonioscope if needed to visualize the location of the stent in the anterior chamber.
- 5) Insert a micro forceps device through the corneal incision and grasp the stent in a convenient and secure manner before removing the stent from the anterior chamber.
- 6) Irrigate the anterior chamber with balanced salt solution (BSS) through the corneal wound to remove all viscoelastic. Press down on the posterior edge of the incision as needed to facilitate complete removal of viscoelastic. Repeat as needed until all viscoelastic has been removed.
- 7) Inflate the anterior chamber with saline solution as needed to achieve normal physiologic pressure.
- 8) Ensure that the corneal incision is sealed.

### **WARNINGS/PRECAUTIONS**

- For prescription use only.
- Intended users are trained ophthalmologists only.
- This device has not been studied in patients with uveitic glaucoma.
- Do not use the device if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised.
- Due to the sharpness of certain injector components (i.e., the insertion sleeve and trocar), care should be exercised to grasp the injector body. Dispose of device in a sharps container.
- iStent infinite is MR-Conditional; see MRI Information below.
- Physician training is required prior to use of the iStent infinite System. Training consists of:
  - Didactic session
  - Simulated implantation of iStent infinite System
  - Supervised iStent infinite System implantation of clinical cases until implantation proficiency is demonstrated.
- Do not re-use the stent(s) or injector, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative

## iStent infinite® Trabecular Micro-Bypass System

### INSTRUCTIONS FOR USE

adverse events as shown below under "Potential Complications."

- There are no known compatibility issues with the iStent infinite and other intraoperative devices (e.g., viscoelastics) or glaucoma medications.
- Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and contaminated products must be disposed of as medical waste.
- The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate treatment regimen to reduce intraocular pressure.
- Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients can enhance the formation or progression of cataract.

#### **POTENTIAL COMPLICATIONS**

Intraoperative or postoperative adverse events may be device-related or non-device related.

Potential intraoperative events are as follows:

- Choroidal hemorrhage or effusion
- Crystalline lens touched by injector
- Posterior capsular bag rupture, in case of combined cataract surgery
- Prolonged anterior chamber collapse
- Significant corneal injury
- Significant damage to trabecular meshwork
- Significant hyphema
- Significant iris damage
- Vitreous loss or vitrectomy, in case of combined cataract surgery
- Stent malposition or loose stent inside eye requiring reacquisition

Potential postoperative events are as follows:

- Choroidal complication (massive hemorrhage or effusion)
- Chronic hypotony
- Clinically significant cystoid macular edema
- Endophthalmitis
- Flat anterior chamber
- Significant loss of best corrected visual acuity (BCVA)
- Intraocular inflammation arising after the prescribed medication regimen is complete
- IOL dislocation (in pseudophakic eyes)
- IOP increase requiring management with oral or intravenous medications or with surgical intervention
- Pupillary block
- Retinal complications (dialysis, flap tears, detachment, or proliferative vitreoretinopathy)
- Secondary surgical intervention including, but not limited to, the following :
  - Trabeculectomy
  - IOL repositioning or removal
  - Stent repositioning or removal
- Significant corneal complications including edema, opacification, decompensation
- Significant damage to the trabecular meshwork
- Significant hyphema
- Significant iris damage
- Stent dislocation or malposition
- Stent obstruction

#### **STORAGE REQUIREMENTS**

The device should be stored at room temperature (15-30°C).

#### **IMPLANT CARD**

An implant identification card is supplied in the device packaging. This card should be given to the patient with instructions to keep as a permanent record of the implant and show to future health care providers. The implant card also identifies the stent as "MR Conditional" and should be shown to health care providers if the patient needs to undergo an MRI.

#### **PRODUCT COMPLAINTS & SERIOUS INCIDENT REPORTING**

Product complaints, incidents, and serious incidents should immediately be reported to Glaukos Medical Safety at [MedicalSafety@glaukos.com](mailto:MedicalSafety@glaukos.com). Serious incidents should also be reported to the National Competent Authority of the Member State where the user/patient resides.

#### **MRI INFORMATION**



#### **Static magnetic field of 3-Tesla or less:**

Non-clinical testing has demonstrated that the iStent infinite Trabecular Micro-Bypass Stents, Model iS3 are MR Conditional.

A patient with this device can be safely scanned in an MR system meeting the following conditions:

- Static magnetic field: 3-Tesla or less
- Maximum spatial gradient magnetic field of 4,000 gauss/cm (40 T/m)
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4-W/kg (First Level Controlled Operating Mode)

Under the scan conditions defined above, the iStent infinite Trabecular Micro-Bypass Stent, Model iS3 is not expected to produce a clinically significant temperature rise after 15 minutes of continuous scanning.

In non-clinical testing, the image artifact caused by the device extends less than 15 mm from the device when imaged with a gradient echo pulse sequence and a 3.0 T MRI system.

#### **Static magnetic field of 7-Tesla, OUS ONLY:**

Non-clinical testing demonstrated that the iStent infinite Trabecular Micro-Bypass Stents, Model iS3 are MR Conditional.

## iStent infinite® Trabecular Micro-Bypass System

### INSTRUCTIONS FOR USE

A patient with this device can be safely scanned immediately after implantation in an MR system meeting the following conditions:

- Static magnetic field of 7-Tesla, ONLY
- Maximum spatial gradient magnetic field of 10,000-gauss/cm (extrapolated) or less
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4-W/kg for 15 minutes of scanning (i.e., per pulse sequence)
- First Level Controlled Operating Mode of operation for the MR system
- Use of a transmit/receive RF head coil, ONLY

#### MRI-Related Heating

In non-clinical testing, the device produced a temperature rise of 0.4°C during MRI performed for 15-minutes of scanning (i.e., per pulse sequence) in a 7-Tesla/298-MHz MR system (Philips Achieva, Philips

Healthcare, Cleveland, OH) using at transmit/receive RF head coil.
















MR system reported, whole body averaged: SAR < 1-W/kg.











#### Artifact Information

In non-clinical testing, the image artifact caused by the device extends approximately 23-mm from this device when imaged using a gradient echo pulse sequence and a 7-Tesla MR system.

#### LABELING

The following symbols are used on the device packaging.

<i>Symbol</i>	<i>Definition</i>
	Catalogue/Model Number
	Serial Number (for the stent)
	Lot Number
	Do not reuse
 yyyy-mm-dd	Use By (year-month-day)
	Do not use if package is damaged
	Sterilized by Gamma Irradiation
	Temperature Storage Requirements
	CE Marking
	MR Conditional
<b>Rx Only</b>	For Prescription use only
	Consult Instructions For Use
	Manufacturer
	Authorized representative in the European Community
	Medical Device
	Contains biological Material of animal origin

<i>Symbol</i>	<i>Definition</i>
	Implant Date
	Health care centre or doctor
	Patient name
	Patient Information website
	Patient number
	Importer
	Unique Device Identifier
	Quantity
	Single sterile barrier system with protective packaging outside
	Date of manufacture



Glaukos Netherlands B.V.  
Kloosterweg 1  
NL - 6412 CN Heerlen  
Tel: +31.20.2801.862  
Fax: +31.20.2807.877  
AuthorizedRepNL@glaukos.com

  
2797



Glaukos Corporation  
229 Avenida Fabricante  
San Clemente, CA 92672 US  
Tel: +1.949.367.9600  
Fax: +1.949.367.9984  
www.glaukos.com



Glaukos Germany GmbH  
Klingholzstraße 7,  
DE - 65189 Wiesbaden,  
Tel: +49.611.9777.4403  
Fax: +49.611.9777.4404  
ImporterGmbH@glaukos.com

Glaukos® and iStent infinite® are registered trademarks of Glaukos Corporation.

Tyvek® is a registered trademark of DuPont USA.